1. Home
  2. SRPT vs BPYPO Comparison

SRPT vs BPYPO Comparison

Compare SRPT & BPYPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • BPYPO
  • Stock Information
  • Founded
  • SRPT 1980
  • BPYPO N/A
  • Country
  • SRPT United States
  • BPYPO Bermuda
  • Employees
  • SRPT 1372
  • BPYPO 30200
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • BPYPO Real Estate
  • Sector
  • SRPT Health Care
  • BPYPO Finance
  • Exchange
  • SRPT Nasdaq
  • BPYPO Nasdaq
  • Market Cap
  • SRPT 1.7B
  • BPYPO N/A
  • IPO Year
  • SRPT 1997
  • BPYPO N/A
  • Fundamental
  • Price
  • SRPT $18.19
  • BPYPO $15.25
  • Analyst Decision
  • SRPT Buy
  • BPYPO
  • Analyst Count
  • SRPT 25
  • BPYPO 0
  • Target Price
  • SRPT $64.00
  • BPYPO N/A
  • AVG Volume (30 Days)
  • SRPT 7.9M
  • BPYPO N/A
  • Earning Date
  • SRPT 08-06-2025
  • BPYPO N/A
  • Dividend Yield
  • SRPT N/A
  • BPYPO N/A
  • EPS Growth
  • SRPT N/A
  • BPYPO N/A
  • EPS
  • SRPT N/A
  • BPYPO N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • BPYPO N/A
  • Revenue This Year
  • SRPT $26.87
  • BPYPO N/A
  • Revenue Next Year
  • SRPT $3.15
  • BPYPO N/A
  • P/E Ratio
  • SRPT N/A
  • BPYPO N/A
  • Revenue Growth
  • SRPT 59.15
  • BPYPO N/A
  • 52 Week Low
  • SRPT $16.88
  • BPYPO N/A
  • 52 Week High
  • SRPT $155.95
  • BPYPO N/A
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 23.09
  • BPYPO 63.81
  • Support Level
  • SRPT $16.88
  • BPYPO $14.62
  • Resistance Level
  • SRPT $18.62
  • BPYPO $15.22
  • Average True Range (ATR)
  • SRPT 1.40
  • BPYPO 0.33
  • MACD
  • SRPT 0.09
  • BPYPO 0.05
  • Stochastic Oscillator
  • SRPT 6.41
  • BPYPO 87.40

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

About BPYPO Brookfield Property Partners L.P.

Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.

Share on Social Networks: